- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02421380
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
October 30, 2023 updated by: Memorial Sloan Kettering Cancer Center
The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient.
The study will explore the use of an imaging agent called hyperpolarized [1-13C] pyruvate (HP) with MRI scans.
(MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt.
In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced.
The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
109
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kayvan Keshari, PhD
- Phone Number: 646-888-3631
Study Contact Backup
- Name: Hedvig Hricak, MD, PhD
- Phone Number: 212-639-7284
Study Locations
-
-
New Jersey
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (Consent Only )
-
Contact:
- Kayvan Keshari, PhD
- Phone Number: 646-888-3631
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Kayvan Keshari, PhD
- Phone Number: 646-888-3631
-
Contact:
- Hedvig Hricak, MD, PhD
- Phone Number: 212-639-7284
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for patients with brain lesions. Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation.
- Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and/or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment.
- Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollment.
- This study will include only patients with sarcoma, prostate, breast, brain, metastatic or pancreatic cancer. In the future other patient groups may be included through amendment of this protocol.
Exclusion Criteria:
- Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of [1-13C] pyruvate injection)
- Breast-feeding
- Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
- Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
- Bilirubin > 1.5 x (ULN)
- AST/ALT >2.5 x ULN
- Albumin < 3 g/dl
- GGT > 2.5 x ULN if Alkaline phosphatase > 2.5 x ULN.
- Renal: Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained within 3-4 weeks prior to study enrollment
- Acute major illness (e.g., unstable cardiovascular condition, etc.)
- Standard MRI exclusion criteria will also be applied, including pacemakers and metal clips located in the patient.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hyperpolarized Pyruvate MRI Reproducibility
This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors.
A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
validate HP MRI at MSKCC (are the scans able to be reproduced)
Time Frame: 1 year
|
The imaging will include standard T2-weighted, diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and 1H MR spectroscopic imaging, depending on the solid tumor type.
This multi-parametric data will be used to delineate the tumor as well as compare to HP MRI.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kayvan Keshari, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2015
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
April 13, 2015
First Submitted That Met QC Criteria
April 17, 2015
First Posted (Estimated)
April 20, 2015
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 14-205
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Tumors
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Peking University Cancer Hospital & InstituteRecruiting
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
BayerActive, not recruitingSolid Malignant TumorsFrance, Japan, Taiwan, Korea, Republic of, Spain
-
The First Affiliated Hospital of Guangzhou Medical...Sinotau Pharmaceutical GroupCompletedMalignant Solid TumorsChina
-
AnewPharmaCompletedAdvanced Malignant Solid TumorsChina
-
Tianjin Medical University Cancer Institute and...UnknownMalignant Solid TumorsChina
-
AstraZenecaKuDOS Pharmaceuticals LimitedCompletedMalignant Solid TumorsUnited Kingdom
-
Chinese PLA General HospitalSinotau Pharmaceutical GroupCompletedMalignant Solid TumorsChina
-
SanofiCompletedMalignant Solid TumorsFrance, Spain, United States, Italy
Clinical Trials on Hyperpolarized Pyruvate
-
University of Texas Southwestern Medical CenterEnrolling by invitationTraumatic Brain InjuryUnited States
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
University of Texas Southwestern Medical CenterEnrolling by invitationBreast NeoplasmsUnited States
-
Chang Gung Memorial HospitalNational Science and Technology CouncilNot yet recruitingCervical Cancer | Gynecologic Cancer | Ovarian Cancer | Endometrial CancerTaiwan
-
Sunnybrook Health Sciences CentreRecruitingHypertension | HypertrophyCanada
-
Javier Villaneuva-Meyer, MDNational Institute for Biomedical Imaging and Bioengineering (NIBIB); General...RecruitingMeningiomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Brain NeoplasmUnited States
-
University of Maryland, BaltimoreRecruiting
-
University of Maryland, BaltimoreRecruitingProstate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterSunnybrook Health Sciences CentreEnrolling by invitationHealthy VolunteersUnited States